



## BioLineRx to Present at Biotech Showcase Conference in San Francisco

January 7, 2014

JERUSALEM, Jan. 7, 2014 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the Biotech Showcase 2014 Conference being held at the Parc 55 Wyndham Union Square Hotel in San Francisco, CA.

(Logo: <http://photos.prnewswire.com/prnh/20130730/630769> )

The BioLineRx presentation is scheduled to start at 11:30 a.m. PST (2:30 p.m. EST) on Tuesday, January 14, 2014. A live audio webcast of the presentation will be available online at [BioLineRx's investor web page](#). An archive of the event will also be available for those unable to listen live.

### About BioLineRx

BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx's current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Ikaria Inc. and is in the midst of a pivotal CE-Mark registration trial; BL-5010 for non-surgical removal of skin lesions, which is expected to commence a pivotal CE-mark registration trial in early 2014; BL-8040 for treating acute myeloid leukemia (AML) and other hematological indications, which is in the midst of a Phase 2 study; and BL-7010 for celiac disease, which recently commenced a Phase 1/2 study.

For more information on BioLineRx, please visit [www.biolinerx.com](http://www.biolinerx.com) or download the investor relations mobile device app, which allows users access to the Company's SEC documents, press releases, and events. BioLineRx's IR app is available on the iTunes App Store as well as the Google Play Store.

### Contact:

[Tiberend Strategic Advisors, Inc.](#)

Joshua Drumm, Ph.D.

[jdrumm@tiberend.com](mailto:jdrumm@tiberend.com)

(212) 375-2664

Andrew Mielach

[amielach@tiberend.com](mailto:amielach@tiberend.com)

(212) 375-2694

Or

Tsipi Haitovsky

Public Relations

+972-3-6240871

[tsipih@netvision.net.il](mailto:tsipih@netvision.net.il)

SOURCE BioLineRx